Bicycle Therapeutics plc
NASDAQ:BCYCBiotechnology
-$0.06 today
- Market cap
- $224.30M
- Beta
- 1.54
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$3.14
Volume 0.45M
Average 0.49M
Returns on capital
Bicycle Therapeutics plc management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-35.9%
avg -35.6%
ROIC
-40.7%
avg -43.0%
ROA
-30.5%
avg -34.2%
Analysis
ROA is currently the strongest return metric at -30.5% versus its period average of -34.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Kevin Lee | Chief Executive Officer & Executive Director | USD 1.66M | 58 | 595.87K | 0.86% |
Michael Skynner | Chief Scientific Officer | USD 1M | 57 | 154.73K | 0.22% |
Alistair Milnes | Chief Corporate Development Officer | USD 965.95K | 52 | 136.72K | 0.20% |
Travis Thompson | Chief Financial Officer | USD 948.77K | 46 | — | — |
Jennifer Perry | Chief Operating Officer | USD 909.05K | 52 | — | — |
Michael Charles-Ferguson Hannay | Chief Product & Supply Chain Officer | USD 698.38K | 60 | 92.56K | 0.13% |
Christian Heinis | Scientific Founder | — | — | — | — |
Zafar Qadir | Chief Legal Officer & General Counsel | — | — | — | — |
Phil Jeffrey | Senior Vice President of Pre-Clinical Development | — | — | — | — |
Stephanie Yao | Senior Vice President of Investor Relations and Corporate Communications | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 5, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
49
$522,733.30
Net Transaction Value
−$522,733.30
Net selling
Most Active
Perry Jennifer Scott
11 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 5, 26Oct 5, 2026 | Perry Jennifer Scott Direct | Sell | $1.2K$1,232.28 |
| Oct 5, 26Oct 5, 2026 | Skynner Michael Direct | Sell | $1.8K$1,795.71 |
| Oct 5, 26Oct 5, 2026 | Hannay Michael Charles Ferguson Direct | Sell | $863.9$863.94 |
| Oct 5, 26Oct 5, 2026 | Perry Jennifer Scott Direct | Sell | $107.1$107.10 |
| Oct 5, 26Oct 5, 2026 | Perry Jennifer Scott Direct | Sell | $284.8$284.80 |
| Oct 5, 26Oct 5, 2026 | Perry Jennifer Scott Direct | Sell | $1.2K$1,232.28 |
| Oct 5, 26Oct 5, 2026 | Lee Kevin Direct | Sell | $5.8K$5,847.66 |
| Oct 5, 26Oct 5, 2026 | Thompson Travis Alvin Direct | Sell | $282$282.03 |
| Oct 2, 26Oct 2, 2026 | Hannay Michael Charles Ferguson Direct | Sell | $5.5K$5,454.84 |
| Oct 2, 26Oct 2, 2026 | Thompson Travis Alvin Direct | Sell | $3.1K$3,098.71 |
1–10 of 49
Summary
Insiders reported 0 buys worth $0.00 and 49 sells worth $522,733.30 over the last 12 months. That adds up to net selling of $522,733.30. Perry Jennifer Scott was the most active insider with 11 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +71.2% | +12.4% (5yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at +71.2% over three years. Forward estimates point to Revenue at +12.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Bicycle Therapeutics plc compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about BCYC's management, answered from reported figures.
Who manages BCYC?
Bicycle Therapeutics plc (BCYC) lists 10 active executives. The top listed executive is Christian Heinis, Scientific Founder.
Are BCYC insiders buying or selling?
Recent insider activity shows net buying of $41.88M.
Continue the stock analysis
Jump to another research area for this company.